Imperial College London
Alternate

Professor Neil Poulter

Faculty of Medicine, School of Public Health

Professor of Preventive Cardiovascular Medicine.
 
 
 
//

Contact

 

+44 (0)20 7594 3446n.poulter

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

55Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Oparil:2018:10.1038/nrdp.2018.14,
author = {Oparil, S and Acelajado, MC and Bakris, GL and Berlowitz, DR and Cifkova, R and Dominiczak, AF and Grassi, G and Poulter, NR and Rodgers, A and Whelton, PK},
doi = {10.1038/nrdp.2018.14},
journal = {Nature Reviews Disease Primers},
title = {Hypertension},
url = {http://dx.doi.org/10.1038/nrdp.2018.14},
volume = {4},
year = {2018}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Systemic arterial hypertension is the most important modifiable risk factor for all-cause morbidity and mortality worldwide and is associated with an increased risk of cardiovascular disease (CVD). Fewer than half of those with hypertension are aware of their condition, and many others are aware but not treated or inadequately treated, although successful treatment of hypertension reduces the global burden of disease and mortality. The aetiology of hypertension involves the complex interplay of environmental and pathophysiological factors that affect multiple systems, as well as genetic predisposition. The evaluation of patients with hypertension includes accurate standardized blood pressure (BP) measurement, assessment of the patients’ predicted risk of atherosclerotic CVD and evidence of target-organ damage, and detection of secondary causes of hypertension and presence of comorbidities (such as CVD and kidney disease). Lifestyle changes, including dietary modifications and increased physical activity, are effective in lowering BP and preventing hypertension and its CVD sequelae. Pharmacological therapy is very effective in lowering BP and in preventing CVD outcomes in most patients; first-line antihypertensive medications include angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, dihydropyridine calcium-channel blockers and thiazide diuretics.
AU  - Oparil,S
AU  - Acelajado,MC
AU  - Bakris,GL
AU  - Berlowitz,DR
AU  - Cifkova,R
AU  - Dominiczak,AF
AU  - Grassi,G
AU  - Poulter,NR
AU  - Rodgers,A
AU  - Whelton,PK
DO  - 10.1038/nrdp.2018.14
PY  - 2018///
SN  - 2056-676X
TI  - Hypertension
T2  - Nature Reviews Disease Primers
UR  - http://dx.doi.org/10.1038/nrdp.2018.14
UR  - http://hdl.handle.net/10044/1/60023
VL  - 4
ER  -
Download